Shionogi Clinical Trials in the U.S.
As part of our commitment to addressing unmet medical needs, Shionogi and collaborating organizations are currently enrolling or preparing to enroll participants in clinical trials for infectious diseases, neurology/CNS, metabolic disorders and oncology.
Infectious Disease
Neurology/CNS
Study 204 (ClinicalTrials.gov Identifier: NCT05163808) is a randomized, double-blind, placebo-controlled Phase 2b/3 study that includes cognitive and safety assessments of zatolmilast in adolescent males ages 9-17 with Fragile X syndrome.
Study 302 (ClinicalTrials.gov Identifier: NCT05367960) is an open-label extension study evaluating safety, available to participants with Fragile X syndrome after completing Study 204 or Study 301.
Acute Ischemic Stroke
REvive (ClinicalTrials.gov Identifier: NCT05953480) is a randomized, double-blind, Phase 2b study evaluating the safety and efficacy of redasemtide in adult participants with acute ischemic stroke.